Arcturus Therapeutics Holdings' analyst price target has been revised downward from $69.89 to $65.88. This change reflects analyst concerns over shifting vaccine market dynamics, regulatory uncertainties, and recently moderated revenue growth expectations.

Analysts maintained an Overweight rating and reiterated a $47 price target for Arcturus Therapeutics Holdings, citing anticipated positive catalysts from the upcoming Phase 2 Cystic Fibrosis program readout in early Q3, while the consensus analyst price target remained unchanged at $70.89. Analyst Commentary Addition of an "upside 90-day catalyst watch" due to the upcoming Cystic Fibrosis program catalyst expected in early Q3.